

Daniel M. Bradbury
BioBrit, LLC
2223 Avenida de la Playa
Suite 108
La Jolla CA 92037

Email: dan@biobrit.com
Mobile: (858) 344-6124
Website: www.biobrit.com

Life sciences executive with over 40 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market, and maximize shareholder value.

EXPERIENCE

Managing Member

September 2012 – present

BioBrit, LLC – www.biobrit.com

- Life Sciences Consulting and Investment Firm
- Year End 2025 IRR 18.7%, TVPI 2.0x

Chairman and Co-Founder

October 2025 – present

Equillum, Inc. (2017 – present) / www.equillumbio.com (NASDAQ: EQ)

- Public US Biopharmaceutical Company focused on developing first-in-class therapies to treat severe autoimmune disorders with high unmet medical need

Executive Chairman and Co-Founder

January 2020 – October 2025

Equillum, Inc.

Chief Executive Officer, Chairman and Co-Founder

May 2017 – January 2020

Equillum, Inc.

- Led company in \$72 million initial public offering

President and Chief Executive Officer and Director

March 2007 – August 2012

Amylin Pharmaceuticals, Inc. (1994-2012) / (NASDAQ: AMLN)

- Public US Biopharmaceutical Company focused on developing medicines for the treatment of metabolic diseases – diabetes, obesity and lipodystrophy
- Led process resulting in the sale of Amylin to Bristol-Myers Squibb for \$7 billion
- Led company through a highly complex regulatory process and gained approval of and launched BYDUREON® in USA
- Managed company to positive operating cash flow for the first time in its 24-year history in 2011
- Sued and subsequently settled with Eli Lilly resulting in the return of global rights to exenatide
- Managed company through a complicated proxy challenge from Carl Icahn and Eastbourne Capital
- Drove a global development and commercialization agreement with Takeda for obesity assets
- Restructured Amylin after an FDA safety alert on BYETTA led to a significant decline in revenues

President and Chief Operating Officer and Director

June 2006 – March 2007

Amylin Pharmaceuticals, Inc.

- Responsible to CEO for Research and Development, Regulatory Affairs, Corporate Strategy, Alliance Management and Business Development
- Integral in financial strategy involving raising >\$2 billion through sale of equity and debt since 1998

Chief Operating Officer

June 2003 – June 2006

Amylin Pharmaceuticals, Inc.

- Responsible to CEO for Research and Development, Regulatory Affairs and Business Development
- Gained approval of BYETTA® and SYMLIN® in US and BYETTA® in Europe
- BYETTA® approved in over 90 countries

Executive Vice President

June 2000 – June 2003

Amylin Pharmaceuticals, Inc.

- Responsible to CEO for Finance, Legal, Clinical Research, Discovery, Business Development, Strategic Planning, European Operations, Investor Relations and Corporate Communications
- Instrumental in the negotiation of the \$465M exenatide global development and commercialization agreement with Eli Lilly & Co.
- Lead executive responsible for finance strategy and resource allocation

Senior Vice President, Corporate Development

March 1998 – June 2000

Amylin Pharmaceuticals, Inc.

- Responsible to CEO for Business Development, Strategic Planning, Investor Relations, Corporate Communications and Marketing
- Negotiated sale of Product Development Division to Magellan Labs (now Cardinal)
- Negotiated feasibility and development collaborations with multiple drug delivery companies
- In-licensed multiple patents to enhance patent portfolio of development programs

Vice President, Marketing

June 1995 – March 1998

Amylin Pharmaceuticals, Inc.

- Commercial Liaison Officer Amylin/Johnson & Johnson collaboration and Co-chair Joint Commercialization Committee
- Successfully managed global coordination of SYMLIN™ commercialization planning with Johnson & Johnson commercial teams
- Built global Strategic Marketing Team with national expertise in US and major European markets - team located in San Diego, New Jersey, Oxford (UK), Paris (France) and Dusseldorf (Germany)
- Provided commercial assessment of in-license candidates – AC2993 (exendin-4) & HMR deals

Director, Marketing Amylin Pharmaceuticals

July 1994 – June 1995

Amylin Europe, UK

- Presented market opportunity for Amylin agonist program to multiple pharmaceutical companies as part of Corporate partnership strategy
- Negotiated commercialization relationship in worldwide SYMLIN™ collaboration agreement with Johnson & Johnson
- Implemented worldwide SYMLIN™ medical communications program

Assoc. Director Anti-Infectives, Worldwide Strategic Product Development

February 1991 – July 1994

SmithKline Beecham Pharmaceuticals, UK (1984-1994) / (LSE: GSK)

- Global Pharmaceutical Company focused on developing and commercializing medicines and vaccines
- Focused R&D teams on the key competitive issues relating to the Global antiviral market and negotiated a revised development plan leading to accelerated FAMVIR™ launches
- Initiated DENAVIR™ OTC switch strategy
- Provided strategic and tactical support for successful UK FAMVIR™ launch in January 1994 and US FAMVIR™ launch in July 1994 (FAMVIR™ sold by SB to Novartis for \$1.63BN in August 2000)
- Authored Global Anti-Infectives/Vaccines Therapeutic 15-year strategic plan

Product Group Manager, International Area Marketing
SmithKline Beecham Pharmaceuticals, UK

June 1990 – February 1991

- Successfully initiated Area Marketing program to establish SB in the hospital injectable antibiotics market, e.g. Launched TIMENTIN™ & IV AUGMENTIN™ in Indonesia, relaunched IV AUGMENTIN™ in Saudi Arabia and launched TIMENTIN™ & IV AUGMENTIN™ in Mexico

Area Manager Gulf States, International Division
Beecham Pharmaceuticals, Sharjah, UAE

December 1988 – June 1990

- Managed Area Office. Responsible for two sales forces and six distributors across five markets (Bahrain, Kuwait, Oman, Qatar, UAE). Responsible for Area Profit - 1989 Area Gross Profit growth rate 23%
- Managed area integration of Beecham and SK&F teams

Marketing Supervisor Middle East, International Division
Beecham Pharmaceuticals, UK

October 1987 – December 1988

- Effectively coordinated Middle East promotional activity and conducted numerous representative training courses for Middle East AUGMENTIN™ and BACTROBAN™ launches

International Trainee, International Division
Beecham Pharmaceuticals, UK

September 1984 – October 1987

- Marketing Executive, Marketing and Services Department
- Medical Representative, Beecham Research Laboratories, UK Division
- Area Assistant, International Division

Pre-registration Pharmacist

September 1983 – September 1984

Glaxo Group Research & Northwick Park Hospital, UK

EDUCATION

1983 Nottingham University, UK

- Bachelor of Pharmacy (Hons)
- Registered UK Pharmacist 1984 – 2011

1985 University of West London, UK

- Postgraduate Diploma in Management Studies (DMS)
- Diploma of the Chartered Institute of Marketing (DCIM)

1994 INSEAD, European Institute of Business Administration, France

- International Executive Program

2004 University of California, Los Angeles

- Director Certification Program

HONORS AND AWARDS

- American Diabetes Association's Father of the Year – San Diego Chapter (2011)
- E&Y Entrepreneur of the Year Finalist (2012)
- Corporate Directors Forum Director of the Year Award – Enhancing Economic Value (2012)
- PharmaVOICE 100 Most Inspiring People (2019)
- Corporate Directors Forum Director of the Year award – Lifetime Achievement in Corporate Governance (2023)

BOARDS AND COMMITTEES

Public Boards:

Illumina, Inc. (2004 – 2017) / www.illumina.com (NASDAQ: ILMN)

- Independent Director
- Audit Committee (Chair: 2005 – 2010)
- Compensation Committee
- Nominating and Governance Committee (Chair: 2013 – 2017)

Novacea, Inc. (2005 – 2009) / (NASDAQ: NOVC) – merged with Transcept Pharmaceuticals Inc.

- Independent Director
- Compensation Committee (Chair)
- Nominating and Corporate Governance Committee

Amylin Pharmaceuticals, Inc. (2006 – 2012) / (NASDAQ: AMLN)

Acquired by Bristol-Myers Squibb for \$7 billion

- Director
- Finance and Risk Committee

Geron Corporation (2012 – 2019) / www.geron.com (NASDAQ: GERN)

- Independent Director
- Audit Committee (2012 – 2019)
- Nominating and Governance Committee (2015 – 2019)

Corcept Therapeutics, Inc. (2012 – 2019) / www.corcept.com (NASDAQ: CORT)

- Independent Director
- Compensation Committee (2013 – 2019)
- Nominating and Governance Committee (2016 – 2019)

BioMed Realty Trust, Inc. (2013 – 2016) / www.biomedrealty.com (NYSE: BMR)

Acquired by Blackstone Real Estate Partners VIII L.P. for \$8 billion

- Lead Independent Director
- Compensation Committee
- Nominating and Governance Committee (Chair)

Biocon Limited (2013 – 2022; 2026 – present) / www.biocon.com (NSE: BIOCON)

- Independent Director (2013 – 2022; 2026 – present)
- Audit and Risk Committee (2013 – 2022)
- Stakeholders Relationship (Chair) (2015 – 2022)
- Nomination and Remuneration Committee (2013 – 2015; 2026 – present)
- Audit Committee (2026 – present)
- Science and Technology Transformation Committee (2026 – present)
- Independent Director – Biocon Biologics US, UK, and Ireland (2026 – present)

Syngene International Limited (2015 – 2016) / <http://www.syngeneintl.com> (NSE: SYNGENE)

- Independent Director
- Nomination and Remuneration Committee

Intercept Pharmaceuticals, Inc. (2016 – 2023) / www.interceptpharma.com (NASDAQ: ICPT)

Acquired by Alfasigma S.p.A. for \$800 million

- Independent Director
- Audit Committee (2016 – 2023)
- Nominating and Governance Committee (2016 – 2023)

Equillium, Inc. (2018 – present) / www.equilliumbio.com (NASDAQ: EQ)

- Chairman of the Board (2018 – 2020; 2025 – present)
- Executive Chairman (2020 – 2025)

Castle Biosciences, Inc. (2019 – present) / www.castlebiosciences.com (NASDAQ: CSTL)

- Chairman of the Board

Panacea Acquisition Corporation (2020 – 2021) / (NYSE: PANA.U)

Combined with Nuvation Bio Inc. www.nuvationbio.com

- Chairman of the Board
- Audit Committee (Chair)

Vivani Medical, Inc. (2024 – present) / www.vivani.com (NASDAQ: VANI)

- Independent Director
- Audit Committee
- Compensation Committee (Chair)

Private Boards:

Peninsula Pharmaceuticals, Inc. (2003 – 2005)

Acquired by J&J for \$245 million

- Director

Cerexa, Inc. (2005 – 2006)

Acquired by Forest Laboratories for \$480 million

- Director
- Compensation Committee (Chair)

Castle Biosciences, Inc. (2012 – 2019) / www.castlebiosciences.com

- Chairman of the Board
- Compensation Committee (2012 – 2019)

Microdermis Corporation (2013 – 2018) / www.microdermis.com

- Director
- Audit Committee (Chair)

Freedom Meditech (2013 – 2017) / www.freedom-meditech.com

- Chairman of the Board

DiaVacs, Inc. (2013 – 2019) / www.diavacs.com

- Chairman of the Board

ProSciento, Inc. (2013 – present) / www.prosciento.com

- Director
- Compensation Committee (Chair)

Troia Therapeutics, Inc. (2014 – 2017)

- Chairman of the Board

Liquid Grids, Inc. (2014 – 2021)

Acquired by Femtec Health www.femtechealth.com for \$20 million

- Chairman of the Board

Sensulin, LLC (2014 – present) / www.sensulin.com

- Chairman of the Board

Renova Therapeutics (2014 – 2021) / www.renovatherapeutics.com

- Director
- Compensation Committee (Chair)

SiteOne Therapeutics (2014-2024) / www.siteonetherapeutics.com

- Observer

Thesan Pharmaceuticals, Inc. (2016 – 2017) / www.thesanpharma.com

- Chairman of the Board

Equillium, Inc. (2017 – 2018) / www.equilliumbio.com

- Chairman of the Board

NeuroVia, Inc. (2017 – 2019) / www.neurovia-inc.com

- Chairman of the Board

Biolinq, Inc. (2017 – present) / www.biolinq.me

- Chairman of the Board

DelNova, Inc. (2018 – present) / www.delnova.net

- Chairman of the Board

Biocon Biologics Limited (2018 – 2026) / <http://www.bioconbiologics.com/>

- Director
- Audit Committee
- Risk Management Committee
- Nomination and Remuneration Committee

IQHQ (2019 – 2024) www.ighqreit.com

- Director
- Audit Committee
- Compensation Committee (Chair)

Synedgen, Inc. (2019 – 2024) / www.synedgen.com

- Director

Alume Biosciences, Inc. (2020 – 2026) / www.alumbiosciences.com

- Executive Chairman of the Board (2025 – 2026)
- Director (2020 – 2025)

AltheaDx, Inc. (2020 – 2022) / <https://www.altheadx.com/>

Acquired by Castle Biosciences www.castlebiosciences.com for \$65 million plus up to \$75 million in milestone payments

- Director

Neuralace Medical Inc. (2020-present) / www.neuralacemedical.com

- Observer

Amplo Biotechnology, Inc. (2021 – present) / www.amplobiotechnology.com

- Executive Chairman of the Board

Abilita Bio, Inc. (2022 – present) / www.abilitabio.com

- Director

Persephone Biosciences, Inc. (2023 – present) / www.persephonebiosciences.com

- Chairman of the Board

Minutia, Inc. (2024 – present) / www.minutia.co

- Chairman of the Board

Tavo Biotherapeutics, Inc. (2025 – present) / www.tavobio.com

- Chairman of the Board

Songbird Health Sciences, Inc. (2026 – present) / www.songbirdhealthsciences.com

- Director

Photo51 Bio, LLC (2026 – present)

- Director

Advisory Boards:

EGS PARTNERS \$100mm Biomedical Investment Fund Advisory Board (2000 – 2009)

- Advisor

RAND Health Board of Advisors (2008 – 2013) / www.rand.org

- Advisor

University of Miami's Innovation Corporate Advisory Council (2009 – 2014)

- Advisor

Patricia Industries (a part of Investor AB) (2010 – 2017) / <http://www.patriciaindustries.com>

**formerly Investor Growth Capital*

- Advisor

BioMed Ventures Advisory Committee (2011 – 2019) / www.biomedrealty.com

- Advisor

AmideBio LLC Advisory Board (2013 – present) / www.amidebio.com

- Advisor

Pharming Group N.V. Commercial Advisory Board (2017 – 2022) / www.pharming.com

- Chairman of the Board

ProLynx, LLC Advisory Board (2017 – present) / www.prolynxllc.com

- Advisor

Arctic Aurora Life Science Advisory Board (2017 – 2019) / <https://www.arctic.com/afm/department/our-funds/#arctic-aurora-lifescience>

- Advisor

Nano Precision Medical/Vivani Advisory Board (2017 – 2024) / www.vivani.com

- Advisor

Minutia (2020 – 2024) / www.minutia.co

- Advisor

Persephone Biosciences (2018 – 2023) / www.persephonebiosciences.com

- Advisor

IMIDomics (2021 – Present) / www.imidomics.com

- Advisor

Abilita Bio (2021 – 2022) / www.abilitabio.com

- Advisor

AXA Investment Managers UK, Global Health Private Equity Advisory Board (2022 – Present) / <https://alts.axa-im.com/investment-expertise/private-equity-and-infrastructure/healthcare>

- Advisor

Medical Excellence Capital Advisory Board (2022 – Present) / www.medexcelcap.com

- Advisor

RNAV8 Bio (2024 – Present) / www.rnav8bio.com

- Advisor

Intrinsic Medicine (2024 – Present) / www.intrinsicmedicine.com

- Advisor

Navega Therapeutics (2024 – Present) / www.navegatx.com

- Advisor

BRT Biotechnologies (2024 – Present) / www.brtbio.com

- Advisor

XenoMet (2025 – Present) / website pending

- Advisor

Aria Therapeutics, Inc. (2025 – Present) / website pending

- Advisor

NeuraClick (2025 – Present) / www.neuraclicktx.com

- Advisor

TIXiMed (2025 – Present) / www.tiximed.com

- Advisor

Courage Therapeutics (2025 – Present) / www.couragetx.com

- Advisor

Non-Profit Boards:

Keck Graduate Institute (a Claremont College) (2006 – present) / www.kgi.edu

- Member of the Board of Trustees
- Executive Committee (2023 – present)
- Budget and Finance Committee (2007 – 2015)
- Audit and Risk Committee (2008 – 2012 / Chair 2015 – 2023, 2024 - present)
- Advancement Committee (2006 – 2009 / 2012 – 2015)
- Chairman of the KGI Advisory Council (2003 – 2006)

UCSD Rady School of Management (2006 – present) / www.rady.ucsd.edu

- Member of the Dean's Advisory Council

Pharmaceutical Research and Manufacturers of America (2007 – 2010) / www.phrma.org

- Director

BIOCOM (2007 – 2012) / www.biocom.org

- Director (Chair 2010)

Riecken Community Libraries (2013 – present) / www.riecken.org

- Director

ADCY5.org (2016 – present) / www.ADCY5.org

- Chairman of the Board

The San Diego Exploratory Foundation (SDEF) (2017 – 2019) / <https://awbgsandiego.com/about/>

- Member of the World Beach Games 2019 Committee